TAK-755 clinical trials
TAK-755 is named as an intervention in 3 current clinical trials in our Japan, UK, USA, China, Germany, France, India, Belgium, Brazil, Spain, Italy, Poland, Switzerland and Austria registers. 2 are recruiting patients now. The most common phase is Phase 2. The lead sponsor is Takeda. The most-studied condition is Thrombotic Thrombocytopenic Purpura (TTP).
Where TAK-755 is approved
All regulators →Of the three regulators tracked here, the first to approve TAK-755 was the EU, on 1 Aug 2024.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
TAK-755 patents and exclusivity
Expiry tracker →Protections still running for marketed products containing TAK-755, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- ADZYNMA for treatment of thrombotic thrombocytopenic purpura: until 2 Aug 2036 (includes 24 months' paediatric extension). Union Register
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
How TAK-755 works
All drug targets →- A disintegrin and metalloproteinase with thrombospondin motifs 13 exogenous protein Exogenous proteinTarget: ADAMTS13 ADAM metallopeptidase with thrombospondin type 1 motif 13ChEMBL only
- Congenital thrombotic thrombocytopenic purpuraPhase 3
- Sickle cell diseasePhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4594607, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for TAK-755
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- EUEuropean Union: AdzynmaEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of TAK-755
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of TAK-755 in Adults With Acute Ischemic Stroke
NCT07392450 · Acute Ischemic Stroke
|
Phase 2 | Recruiting | Takeda | UK, USA, India, China, Germany, France, Belgium, Brazil, Japan |
|
A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
NCT06441578 · ClinicalTrials.gov ↗ · Thrombotic Thrombocytopenic Purpura (TTP)
|
Observational | Recruiting | Takeda | Japan |
|
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
NCT04683003 · Thrombotic Thrombocytopenic Purpura (TTP)
|
Phase 3 | Active, closed | Takeda | UK, USA, China, Germany, France, Spain, Italy, Poland, Switzerland, Austria, Japan |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with TAK-755
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Takeda | 3 |
By country register
A trial with sites in more than one country appears in each of those registers.
Questions about TAK-755 trials
How many clinical trials are testing TAK-755?
3 current trials in our Japan, UK, USA, China, Germany, France, India, Belgium, Brazil, Spain, Italy, Poland, Switzerland and Austria registers name TAK-755 (also registered as RADAMTS13) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are TAK-755 trials recruiting patients?
Yes. 2 of the 3 trials are recruiting: 2 with sites in Japan, 1 with sites in UK, 1 with sites in USA, 1 with sites in China, 1 with sites in Germany, 1 with sites in France, 1 with sites in India, 1 with sites in Belgium and 1 with sites in Brazil. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors TAK-755 clinical trials?
The lead sponsor is Takeda. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how TAK-755 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how TAK-755 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists TAK-755 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.